系统性硬化症相关间质性肺病中肺动脉高压的患病率、治疗与结局
该前瞻性观察队列纳入93例系统性硬化症相关间质性肺病(SSc-ILD)患者,按标准化算法筛查并经右心导管确诊肺动脉高压(PH)。31.2%存在右心导管证实的PH,多数为WHO第3组,常在SSc起病7年内诊断,多数接受ILD及PAH治疗,生存良好。
要点
- SSc-ILD患者中31.2%经右心导管确诊PH,应常规评估共存PH。
- 确诊PH者中55.2%为WHO第3组PH,24.1%为PAH。
- 48.3%的PH在SSc起病7年内诊断,提示PH可早期出现。
核心结论
- 在SSc-ILD大型队列中,相当比例患者共存PH,且常在SSc诊断后早期出现,多数接受ILD和PAH治疗,生存良好。
研究设计与样本
- 前瞻性观察队列纳入93例经高分辨率CT诊断的SSc-ILD患者,按标准化算法筛查PH,必要时行右心导管检查,PH分类基于血流动力学和HRCT间质性肺病范围。
主要发现
- 93例SSc-ILD患者中76%为女性,65.6%为弥漫性皮肤型SSc,平均年龄54.9岁,平均SSc病程8年。
- 29例(31.2%)有右心导管证实的PH;其中24.1%为PAH,55.2%为WHO第3组PH,34.5%为WHO第3组PH且肺血管阻力>3.0 Wood单位。
- 48.3%的PH在SSc起病7年内诊断,82.8%接受ILD治疗,82.8%接受PAH治疗。
- 所有患者SSc-ILD诊断后3年生存率为97%;SSc-ILD合并PH患者PH诊断后3年生存率为91%。
临床怎么用
- 对SSc-ILD患者应按标准化算法筛查并评估共存PH,必要时行右心导管检查确诊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic sclerosis (SSc) is associated with interstitial lung disease (ILD) and pulmonary hypertension (PH). This study was undertaken to determine the prevalence, characteristics, treatment, and outcomes of PH in a cohort of patients with SSc-associated ILD. METHODS: Patients with SSc-associated ILD on high-resolution computed tomography (HRCT) were included in a prospective observational cohort. Patients were screened for PH based on a standardized screening algorithm and underwent right-sided heart catheterization (RHC) if indicated. PH classification was based on hemodynamic findings and the extent of ILD on HRCT. Summary statistics and survival using the Kaplan-Meier method were calculated. RESULTS: Of the 93 patients with SSc-associated ILD included in the study, 76% were women and 65.6% had diffuse cutaneous SSc. The mean age was 54.9 years, and the mean SSc disease duration was 8 years. Twenty-nine patients (31.2%) had RHC-proven PH; of those 29 patients, 24.1% had PAH, 55.2% had World Health Organization (WHO) Group III PH, 34.5% had WHO Group III PH with pulmonary vascular resistance >3.0 Wood units, 48.3% had a PH diagnosis within 7 years of SSc onset, 82.8% received therapy for ILD, and 82.8% received therapy for PAH. The survival rate 3 years after SSc-associated ILD diagnosis for all patients was 97%. The survival rate 3 years after PH diagnosis for those with SSc-associated ILD and PH was 91%. CONCLUSION: In a large cohort of patients with SSc-associated ILD, a significant proportion of patients had coexisting PH, which often occurs early after SSc diagnosis. Most patients were treated with ILD and PAH therapies, and survival was good. Patients with SSc-associated ILD should be evaluated for coexisting PH.
引用
- Young A, Vummidi D, Visovatti S, et al. Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis. Arthritis Rheumatol. 2019. PMID: 30762947. doi:10.1002/art.40862
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。